X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
VENUS REMEDIES Fact Sheet, VENUS REMEDIES Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES Fact Sheet   (VSRM)

Here is the latest financial fact sheet of VENUS REMEDIES. For more details, see the VENUS REMEDIES quarterly results and VENUS REMEDIES share price and chart. For a sector overview, read our pharmaceuticals sector report.

VENUS REMEDIES Price History

Price Rs 94.4
Mkt Cap Rs m 1,080
Vol '000 16.5
P/E X -843.7
P/CF X 2.5
EPS (TTM) Rs -0.1
% ch % -0.7
No. of shares m 11.44
% ch week % -0.2
% ch 1-mth % -4.3
% ch 12-mth % 19.0
52 week H/L Rs 142.8/72.8
(As on Jun 23, 2017 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

VENUS REMEDIES Financials

No. of Mths
Year Ending
12
Mar-12
*
12
Mar-13
*
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
5-Yr Chart
Click to enlarge
VENUS REMEDIES EQUITY SHARE DATA
High Rs276328358330218 
Low Rs14115814010382 
Sales per share (Unadj.) Rs420.8444.6473.4405.6365.6 
Earnings per share (Unadj.) Rs48.354.456.24.51.5 
Diluted earnings per shareRs41.150.156.24.51.5 
Cash flow per share (Unadj.) Rs74.285.891.444.737.9 
Dividends per share (Unadj.) Rs3.003.00000 
Adj. dividends per shareRs2.552.760.000.000.00 
Dividend yield (eoy) %1.41.2000 
Book value per share (Unadj.) Rs315.5359.7403.5399.2382.5 
Adj. book value per shareRs268.6331.4403.5399.2382.5 
Shares outstanding (eoy) m9.7410.5411.4411.4411.44 
Bonus/Rights/Conversions  WCWCWC-- 
Price / Sales ratio x0.50.50.50.50.4 
Avg P/E ratio x4.34.54.447.9101.0 
P/CF ratio (eoy) x2.82.82.74.84.0 
Price / Book Value ratio x0.70.70.60.50.4 
Dividend payout %6.25.5000 
Avg Mkt Cap Rs m2,0312,5602,8492,4711,717 
No. of employees `000NANANANA1.0 
Total wages/salary Rs m248273305324324 
Avg. sales/employee Rs ThNMNMNMNM4,100.7 
Avg. wages/employee Rs ThNMNMNMNM318.0 
Avg. net profit/employee Rs ThNMNMNMNM16.7 
VENUS REMEDIES INCOME DATA
Net Sales Rs m4,0984,6865,4164,6404,183 
Other income Rs m545720 
Total revenues Rs m4,1034,6915,4204,6474,203 
Gross profit Rs m1,0311,2011,382892812 
Depreciation Rs m252331402460417 
Interest Rs m275246294412380 
Profit before tax Rs m5096286912735 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m385548-2518 
Profit after tax Rs m4715736435217 
Gross profit margin %25.225.625.519.219.4 
Effective tax rate %7.48.86.9-94.851.6 
Net profit margin %11.512.211.91.10.4 
VENUS REMEDIES BALANCE SHEET DATA
Current assets Rs m1,6962,2562,7212,6752,771 
Current liabilities Rs m1,5321,9132,1101,9651,931 
Net working cap to sales %4.07.311.315.320.1 
Current ratio x1.11.21.31.41.4 
Inventory Days Days8610096112125 
Debtors Days Days3637445054 
Net fixed assets Rs m2,0544,0565,0735,2195,328 
Share capital Rs m97105114114114 
"Free" reserves Rs m2,0782,6064,4504,4454,177 
Net worth Rs m3,0733,7914,6164,5674,376 
Long term debt Rs m9911,2911,4001,6861,911 
Total assets Rs m5,7407,1768,3448,4118,428 
Interest coverage x2.83.63.31.11.1 
Debt to equity ratio x0.30.30.30.40.4 
Sales to assets ratio x0.70.70.60.60.5 
Return on assets %13.011.411.25.54.7 
Return on equity %15.315.113.91.10.4 
Return on capital %19.317.216.47.06.6 
Exports to sales %00000 
Imports to sales %13.214.817.017.720.5 
Exports (fob) Rs m00000 
Imports (cif) Rs m542695921821858 
Fx inflow Rs m00000 
Fx outflow Rs m00921822858 
Net fx Rs m00-921-822-858 
VENUS REMEDIES CASH FLOW
From Operations Rs m 417 522 527 678 469 
From Investments Rs m -952 -1,039 -947 -672 29 
From Financial Activity Rs m 533 552 401 -14 -464 
Net Cashflow Rs m -2 34 -20 -8 35 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 32.9%
Foreign collaborators 0.0%
Indian inst/Mut Fund 0.2%
FIIs 0.6%
ADR/GDR 0.0%
Free float 66.4%
Shareholders 20,121
Pledged promoter(s) holding 36.4%
 

Company Information

REGD OFF SCO 857, 2nd Floor, Cabin No. 10, NAC Manimajra, Chandigarh-160 101
E-MAIL investorgrievance@venusremedies.com WEB www.venusremedies.com
TELEPHONE (0172) 393 3094 FAX (0172) 256 5566
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Link Intime India, A-31, Naraina Indl. Area, Phase 1, New Delhi-28
AUDITOR J. K. Jain & Assoc.
CHM: Pawan Chaudhary (MD) COMP SEC: Neha Kodan YEAR OF INC: 1989 BSE CODE: 526953 FV (Rs): 10 DIV YIELD (%): -

More Pharmaceuticals Company Fact Sheets:   NOVARTIS  J.B.CHEMICALS  ELDER PHARMA  PLETHICO PHARMA  IPCA LABS  

Compare VENUS REMEDIES With:   NOVARTIS  J.B.CHEMICALS  ELDER PHARMA  PLETHICO PHARMA  IPCA LABS  

Compare VENUS REMEDIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Share Markets End the Week on a Dull Note(RoundUp)

Global financial markets ended the week on a dull note. This was on back of the Federal Reserve's release of its May 2-3 policy meeting minutes.

Views on news

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

More Views on News

Most Popular

Digital Transactions were Growing Faster Before Demonetisation(Vivek Kaul's Diary)

Jun 12, 2017

Which brings us back to the basic question, why was demonetisation carried out?

A Pharma IPO in a Market That Loves IPOs but Hates Pharma(The 5 Minute Wrapup)

Jun 15, 2017

Tomorrow comes the IPO of Eris Lifesciences. How will a pharma IPO do in this market?

Get Ready for Commodity Options!(Daily Profit Hunter)

Jun 16, 2017

Commodity options trading is one step closer to reality. Learn how to take advantage of this tremendous opportunity.

Walter Schloss' Investing Record(Chart Of The Day)

Jun 17, 2017

In a market full of one-hit-wonders, this investor obviously had a formula that worked. And through the think-and-thin of the market.

11 Hidden Costs Associated With Your Home Loan(Outside View)

Jun 16, 2017

Various costs associated with a home loan.

More

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS